Big M&A rumors continue to swirl round the pharma world this summer, with talk of a Pfizer bid for Global Blood Therapeutics in the offing.
While the signs are that Pfizer is in advanced talks to complete the acquisition for around $5 billion, a rumored deal that has not yet happened has been Merck & Co's (NYSE: MRK) potential buy of US biotech Seagen (Nasdaq: SGEN).
In terms of what was announced in July, Anglo-Swedish pharma major AstraZeneca (LSE: AZN) was the only big pharma player to enter the M&A market, acquiring USA-based biotech TeneoTwo for $100 million upfront.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze